Table 1. Change of gene expression relating to cell cycle, glioma development, cytokine-cytokine receptor interaction, ECM-receptor interaction, cell adhesion molecule, PI3K-AKT, MAPK and RAS signaling pathway after treatment of small molecules.

Related Pathway	Significantly down-regulated genes	Significantly up-regulated genes
Cell cycle	CCNA2 (-4.56), CDC25B (-4.03), PLK1 (-5.04), MCM7 (-4.10), CCNB2 (-5.06), PTTG1 (-5.35), CDC20 (-4.14), CDK4 (-2.94), CDK6 (-3.18)	NA
Glioma development	PDGFRA (-16.57), PDGFRB (-5.39)	NA
Cytokine-receptor interaction	MET (-4.29), PDGFRB (-5.39), PDGFRA (-16.57), CSF1 (-5.49)	NGFR (4.07)
ECM-receptor interaction	RELN (-7.27), ITGA1 (-4.96), SPP1 (-22.95), COL1A1 (-4.76), COL6A1 (-6.58), LAMA2 (-5.50), LAMA4 (-4.01), ITGA4 (-5.45), ITGB8 (-16.93)	NA
Cell adhesion molecule	SDC3 (13.1), CD28 (-5.10), RT1-S3 (-5.39), PTPRM (-4.25), ITGA4 (-5.45), ITGB8 (-16.93)	NRCAM (174.65)
PI3K/AKT signaling pathway	LPAR1 (-6.25), MET (-4.29), PDGFRB (-5.39), RELN (-7.27), ITGA1 (-4.96), PDGFRA (-16.57), SPP1 (-22.95), COL1A1 (-4.76), COL6A1 (-6.58), LAMA2 (-5.50), LAMA4 (-4.01), ITGA4 (-5.45), PCK2 (-4.37), ITGB8 (-16.93), CSF1 (-5.49), PRKAA2 (-4.06), NF-ҡB (-2.76)	NGFR (4.07)
MAPK signaling pathway	CDC25B (-4.03), PDGFRB (-5.39), NTRK2 (-7.48), PDGFRA (-16.57), RAPGEF2 (-4.26), RPS6KA5 (-4.57), MEF2C (-16.48)	NA
RAS signaling pathway	ETS1 (-5.26), MET (-4.29), PDGFRB (-5.39), PDGFRA (-16.57), CSF1 (-5.49), KRAS (-2.52), NRAS (-2.32)	NGFR (4.07)